Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis
A live, multi-source view of Ultragenyx Pharmaceutical Inc. (RARE): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Sector: Healthcare · Industry: Biotechnology · United States · 1,371 employees · ultragenyx.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Ultragenyx Pharmaceutical Inc. (RARE) had a market capitalization of $1.51B (forward 75.8) and a beta of 0.32; the shares traded in a 52-week range of $13.81 – $39.89 (-52.9% over the year).
- Market cap
- $1.51B
- Enterprise value
- $2.42B
- Forward P/E
- 75.8
- EPS (trailing)
- $-6.01
- EPS (forward)
- $0.20
- Payout ratio
- 0.0%
- 52-week range
- $13.81 – $39.89
- 52-week change
- -52.9%
- Beta
- 0.32
- Average volume
- 2.9M
- Shares outstanding
- 98.6M
- Short % of float
- 16.67%
- Profit margin
- -81.7%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Ultragenyx Pharmaceutical Inc. (RARE) last closed at $14.40 (the last completed close before that scan).
Technicals at the scan: RSI 20 (oversold territory), price -37.9% versus its 20-day average, 20-day versus 50-day average spread -13.2%, MACD histogram -1.25.
Sentiment inputs: 14% of recent Finnhub-scored headlines read bullish; StockTwits 80% bullish; Reddit mentions 0% over 24 hours; analyst consensus score 66/100.
Next scheduled company event: in 53 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of RARE; corporate insiders filed 0 buys and 3 sells (3 distinct filers, latest disclosure 2026-09-08). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Theodore Alan Huizenga (0B/1S), Karah Herdman Parschauer (0B/1S), Howard Horn (0B/1S). Who is trading what
RapidTradeView pick record
RARE has been a daily pick 1 time; 1 of 1 graded picks beat SPY over the following five trading days. Most recent: 2026-08-20, rank #3, +2.60% versus SPY (beat). Full scoreboard
What this page covers
RapidTradeView pulls Ultragenyx Pharmaceutical Inc. (RARE) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell RARE.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.